On August 6, 2025, Fortune unveiled its annual 100 Most Powerful People in Business list, spotlighting Dr. Reshma Kewalramani, CEO and President of Vertex Pharmaceuticals. Born in Bombay and relocating to the U.S. at age 11, Kewalramani’s inclusion underscores not only her leadership in biotech but also the growing prominence of Indian‑American executives in global corporate governance.
Why Reshma Kewalramani Makes the Cut
Since assuming the CEO role at Vertex in April 2020, Kewalramani has led:
• Casgevy, the first CRISPR‑based gene ‑ editing therapy approved for sickle cell disease and beta thalassemia
• Expansion of approved treatments for cystic fibrosis and the launch of Journavx, the first novel non‑opioid chronic pain drug in decades
• Strengthening Vertex’s pipeline into APOL1 ‑ mediated kidney disease and cell therapies for type 1 diabetes
Fortune’s inclusion reflects both performance and potential. At a time when pharma is under pressure to deliver breakthrough therapies – and deliver responsibly – Kewalramani has balanced scientific innovation with cost efficiency and diversity mandates.
Broader Impact & Representation
Leadership symmetry:As a woman of Indian origin leading a Fortune 500 biotech, she shatters multiple glass ceilings simultaneously.
Pipeline effect: Her visibility elevates Indian ‑ American female role models in STEM leadership.
Policy influence: Vertex’s advocacy on gene ‑ therapy access and pricing guidance now carries the weight of Fortune‑listed leadership.
